Related content

Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma

By                              

International Journal of Oncology, Vol. 40, Iss. 6, 2012-01 ,pp. : 2140-2146

Spandidos Publications

Access to resources Recommend Favorite

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

By Wheler Jennifer   Janku Filip   Falchook Gerald   Jackson Tiffiny   Fu Siqing   Naing Aung   Tsimberidou Apostalia   Moulder Stacy   Hong David   Yang Hui   Piha-Paul Sarina   Atkins Johnique   Garcia-Manero Guillermo   Kurzrock Razelle  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 495-501

Springer Publishing Company

Access to resources Recommend Favorite

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo

By Tumber Anthony   Collins Laura   Petersen Kamille   Thougaard Annemette   Christiansen Sanne   Dejligbjerg Marielle   Jensen Peter   Sehested Maxwell   Ritchie James  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 275-283

Springer Publishing Company

Access to resources Recommend Favorite

Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells

By    

Oncology Reports, Vol. 29, Iss. 3, 2013-01 ,pp. : 1238-1244

Spandidos Publications

Access to resources Recommend Favorite

Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells

By          

Molecular Medicine Reports, Vol. 11, Iss. 4, 2015-01 ,pp. : 2908-2912

Spandidos Publications

Access to resources Recommend Favorite